Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineLawrence M. Gelbert, Alfonso de Dios|Investigational New Drugs|2014Cited by 564
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V. Bhagwat, Alfonso de Dios|Cancer Research|2024Cited by 19